Davey MG, Kerin E, O'Flaherty C, et al. - By analyzing consecutive women with human epidermal growth factor receptor-2 positive (HER+) breast cancer treated surgically in a single institution between 2005-2015, researchers herein assessed clinicopathological predictors of pathological complete response (pCR) to neoadjuvant therapies as well as examined pCR as a surrogate to enhanced survival. This analysis involved 451 patients (mean age 56.6 ± 13.4 years). A median follow-up of 108.0 months revealed a disease-free and overall survival of 82.3% (371/451) and 82.6% (376/451) respectively. In the neoadjuvant setting, 118 were treated (26.2%): independent predictors of breast pCR included tumour size <50mm and progesterone receptor negativity, while axillary pCR was predicted by ductal carcinoma and grade 3 disease. Findings showed pCR as a sensitive biomarker as well as surrogate to survival results in HER2+ breast cancer. Conventional clinicopathological features and molecular parameters may predict the cases likely to achieve pCR.